Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by DavidKingCanadaon Jul 20, 2021 4:11pm
120 Views
Post# 33576607

Best Case Scenario for PMN

Best Case Scenario for PMN

Would like to hear what others may be thinking;

PMN is a small Canadian Company with a very small Cap and almost no pull in the Industry.

If PMN becomes successful in creating and manufacturing a Serology Test or an actual working and FDA Approved Drug to treat Alzheimers they may and most likely be bought out by much larger US Companies before we can see any Increase in SP.

In all honesty, I don't see PMN holding the torch and running with it.

PMN has "proprietary" Software like many other Companies have stated. How much "proprietary" they have is how much they will be paid. 

<< Previous
Bullboard Posts
Next >>